View Financial HealthBeroni Group 배당 및 자사주 매입배당 기준 점검 0/6Beroni Group 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-72.0%자사주 매입 수익률총 주주 수익률-72.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 01Beroni Group Limited, Annual General Meeting, May 29, 2026Beroni Group Limited, Annual General Meeting, May 29, 2026. Location: at level 16, 175 pitt street, sydney nsw 2000 australia Australia공시 • Aug 30Beroni Group Limited, Annual General Meeting, Oct 01, 2024Beroni Group Limited, Annual General Meeting, Oct 01, 2024. Location: level 16, 175 pitt street, 2000 australia, sydney nsw Australia공시 • Jun 02Beroni Group Limited Announces That It Has Received Notification from Its European Authorized RepresentativeBeroni Group Limited announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its latest enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method (“Rapid Test Kit”) has complied with the applicable essential requirements of the council directive 98/79/EEC in vitro diagnostics as amended. Since its launch in 2020, the Rapid Test Kit has been further optimized and upgraded with greatly improved performance indicators. The enhanced Rapid Test Kit is not only simple and convenient to use but also is further improved with faster detection time and higher level of accuracy.공시 • Apr 01Beroni Group Limited Appoints John Chiplin to the Board of DirectorsBeroni Group Limited announced that it has appointed Dr. John Chiplin as an independent director to Beroni’s Board of Directors effective April 1, 2022. Dr. Chiplin is an accomplished biotech executive and investor with a proven track record of building successful biotech companies. Dr. John Chiplin, PhD is Managing Director of Newstar Ventures Ltd. and Chairman of the Board of Biotherapy Services, N4 Pharma plc and Scancell Holdings plc. Dr. Chiplin has significant operational, investment and international experience in the life science and technology industries. From 2014 to 2016, he served as executive director of Benitec Biopharma Inc. and helped executed the company’s US IPO.공시 • Sep 10Beroni Group Receives Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAOBeroni Group announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure. The approval also includes R&D overseas activities so long as the total overseas expenditure claim over the life of the R&D activities is less than the expected total expenditure on the Australian R&D activities to which they are scientifically linked. The PENAO drug manufacture is expected to complete in the first half of 2022. Raw materials have been procured, familiarization studies have been completed and optimization work is progressing well at Aurigene Pharmaceutical Services Ltd, India.공시 • Sep 02Beroni Group Announces the Latest Clinical Study of its SARS-CoV-2 Antigen Test KitBeroni Group Limited announced the latest clinical study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) demonstrated an overall sensitivity of 95% and specificity of 100%. The clinical study was conducted with 70 subjects providing 105 true-positive specimens and 105 true-negative specimens. The results for the different types of swab sampling are as follows: Nasal sampling - sensitivity 92%; specificity 100%; Nasopharyngeal sampling - sensitivity 97%; specificity 100%; Oropharyngeal sampling - sensitivity 95%; specificity 100%. Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) received CE certification in December 2020 and was granted authorization for export in April 2021. The product can be used for in vitro qualitative auxiliary detection of SARS-CoV-2 antigen specimens and is for professional use only.공시 • May 29Beroni Group Limited announced that it has received $2 million in fundingBeroni Group Limited (NSX:BTG) announced a private placement of 20,000 convertible notes at a price of $100 per note for gross proceeds of $2,000,000 on May 28, 2021. The transaction included participation from an investor in Japan. The notes are zero coupon notes with a maturity date of May 27, 2022 and are convertible into common shares at a conversion price of $10. The number of shares to be issued in respect of each convertible note will be calculated by dividing the face value of the notes by the conversion price. Some or all of the convertible notes can be converted at the election of the noteholder at any time prior to maturity. The notes are issued at par.공시 • Apr 29Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export PermitBeroni Group Limited announced that it has received the notification that its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) is granted authorization for export. This test kit requires no blood, and only a nasopharyngeal swab is needed to collect samples. It can also deliver the test results within 10 minutes. Based on clinical tests, the sensitivity, specificity and total coincidence rate of anterior nasal sampling are 95.90%, 99.19% and 97.55% respectively, while the sensitivity, specificity and total coincidence rate of nasopharyngeal and oropharyngeal sampling are 98.36%, 99.19% and 98.78% respectively.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BNIG.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BNIG.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Beroni Group 배당 수익률 vs 시장BNIG.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BNIG.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (BNIG.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BNIG.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BNIG.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BNIG.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BNIG.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/10/14 02:06종가2025/07/17 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Beroni Group Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 01Beroni Group Limited, Annual General Meeting, May 29, 2026Beroni Group Limited, Annual General Meeting, May 29, 2026. Location: at level 16, 175 pitt street, sydney nsw 2000 australia Australia
공시 • Aug 30Beroni Group Limited, Annual General Meeting, Oct 01, 2024Beroni Group Limited, Annual General Meeting, Oct 01, 2024. Location: level 16, 175 pitt street, 2000 australia, sydney nsw Australia
공시 • Jun 02Beroni Group Limited Announces That It Has Received Notification from Its European Authorized RepresentativeBeroni Group Limited announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its latest enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method (“Rapid Test Kit”) has complied with the applicable essential requirements of the council directive 98/79/EEC in vitro diagnostics as amended. Since its launch in 2020, the Rapid Test Kit has been further optimized and upgraded with greatly improved performance indicators. The enhanced Rapid Test Kit is not only simple and convenient to use but also is further improved with faster detection time and higher level of accuracy.
공시 • Apr 01Beroni Group Limited Appoints John Chiplin to the Board of DirectorsBeroni Group Limited announced that it has appointed Dr. John Chiplin as an independent director to Beroni’s Board of Directors effective April 1, 2022. Dr. Chiplin is an accomplished biotech executive and investor with a proven track record of building successful biotech companies. Dr. John Chiplin, PhD is Managing Director of Newstar Ventures Ltd. and Chairman of the Board of Biotherapy Services, N4 Pharma plc and Scancell Holdings plc. Dr. Chiplin has significant operational, investment and international experience in the life science and technology industries. From 2014 to 2016, he served as executive director of Benitec Biopharma Inc. and helped executed the company’s US IPO.
공시 • Sep 10Beroni Group Receives Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAOBeroni Group announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure. The approval also includes R&D overseas activities so long as the total overseas expenditure claim over the life of the R&D activities is less than the expected total expenditure on the Australian R&D activities to which they are scientifically linked. The PENAO drug manufacture is expected to complete in the first half of 2022. Raw materials have been procured, familiarization studies have been completed and optimization work is progressing well at Aurigene Pharmaceutical Services Ltd, India.
공시 • Sep 02Beroni Group Announces the Latest Clinical Study of its SARS-CoV-2 Antigen Test KitBeroni Group Limited announced the latest clinical study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) demonstrated an overall sensitivity of 95% and specificity of 100%. The clinical study was conducted with 70 subjects providing 105 true-positive specimens and 105 true-negative specimens. The results for the different types of swab sampling are as follows: Nasal sampling - sensitivity 92%; specificity 100%; Nasopharyngeal sampling - sensitivity 97%; specificity 100%; Oropharyngeal sampling - sensitivity 95%; specificity 100%. Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) received CE certification in December 2020 and was granted authorization for export in April 2021. The product can be used for in vitro qualitative auxiliary detection of SARS-CoV-2 antigen specimens and is for professional use only.
공시 • May 29Beroni Group Limited announced that it has received $2 million in fundingBeroni Group Limited (NSX:BTG) announced a private placement of 20,000 convertible notes at a price of $100 per note for gross proceeds of $2,000,000 on May 28, 2021. The transaction included participation from an investor in Japan. The notes are zero coupon notes with a maturity date of May 27, 2022 and are convertible into common shares at a conversion price of $10. The number of shares to be issued in respect of each convertible note will be calculated by dividing the face value of the notes by the conversion price. Some or all of the convertible notes can be converted at the election of the noteholder at any time prior to maturity. The notes are issued at par.
공시 • Apr 29Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export PermitBeroni Group Limited announced that it has received the notification that its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) is granted authorization for export. This test kit requires no blood, and only a nasopharyngeal swab is needed to collect samples. It can also deliver the test results within 10 minutes. Based on clinical tests, the sensitivity, specificity and total coincidence rate of anterior nasal sampling are 95.90%, 99.19% and 97.55% respectively, while the sensitivity, specificity and total coincidence rate of nasopharyngeal and oropharyngeal sampling are 98.36%, 99.19% and 98.78% respectively.